ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

Summary

To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-008 given every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule.

Timeline

Start

2007-04-01

Primary completion

2011-06-02

Completion

2011-06-02

Drugs

Indications